UiPath (NYSE:PATH) Price Target Raised to $24.00 at DA Davidson

UiPath (NYSE:PATH) had its price target raised by DA Davidson from $20.00 to $24.00 in a research report sent to investors on Thursday, Benzinga reports. DA Davidson currently has a neutral rating on the healthcare company’s stock.

Several other equities research analysts have also recently weighed in on PATH. Morgan Stanley boosted their target price on UiPath from $17.00 to $25.00 and gave the stock an equal weight rating in a research note on Thursday. Royal Bank of Canada boosted their target price on UiPath from $27.00 to $29.00 and gave the stock a sector perform rating in a research note on Thursday. Canaccord Genuity Group boosted their target price on UiPath from $27.00 to $30.00 and gave the stock a buy rating in a research note on Friday. Wells Fargo & Company boosted their target price on UiPath from $18.00 to $20.00 and gave the stock an equal weight rating in a research note on Friday, December 1st. Finally, Mizuho lifted their price target on UiPath from $22.00 to $25.00 and gave the stock a neutral rating in a research report on Thursday. Nine investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of Hold and an average price target of $27.13.

UiPath Trading Up 1.4 %

UiPath stock traded up $0.32 during midday trading on Thursday, reaching $23.07. 9,842,354 shares of the stock traded hands, compared to its average volume of 10,074,664. The company has a 50-day simple moving average of $23.52 and a two-hundred day simple moving average of $20.70. The firm has a market cap of $13.06 billion, a PE ratio of -135.46 and a beta of 0.97. UiPath has a 12-month low of $12.38 and a 12-month high of $27.87.

Insiders Place Their Bets

In other UiPath news, Director Rich Wong sold 200,000 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the completion of the sale, the director now directly owns 429,418 shares in the company, valued at $9,928,144.16. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, CFO Ashim Gupta sold 125,000 shares of the business’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $22.59, for a total value of $2,823,750.00. Following the completion of the sale, the chief financial officer now directly owns 858,148 shares of the company’s stock, valued at $19,385,563.32. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Rich Wong sold 200,000 shares of the business’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $23.12, for a total value of $4,624,000.00. Following the completion of the sale, the director now directly owns 429,418 shares of the company’s stock, valued at $9,928,144.16. The disclosure for this sale can be found here. Insiders sold a total of 411,000 shares of company stock worth $9,418,670 over the last ninety days. 31.03% of the stock is owned by company insiders.

Institutional Trading of UiPath

Several hedge funds and other institutional investors have recently bought and sold shares of PATH. Intech Investment Management LLC boosted its position in shares of UiPath by 3.1% during the fourth quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company’s stock worth $356,000 after buying an additional 426 shares during the period. 180 Wealth Advisors LLC boosted its position in shares of UiPath by 0.3% during the fourth quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company’s stock worth $4,497,000 after buying an additional 492 shares during the period. Bleakley Financial Group LLC lifted its position in UiPath by 4.9% in the fourth quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company’s stock worth $315,000 after purchasing an additional 598 shares during the period. Simplicity Solutions LLC lifted its position in UiPath by 4.9% in the fourth quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company’s stock worth $315,000 after purchasing an additional 598 shares during the period. Finally, Creative Planning lifted its position in UiPath by 7.0% in the second quarter. Creative Planning now owns 10,163 shares of the healthcare company’s stock worth $185,000 after purchasing an additional 666 shares during the period. 59.04% of the stock is owned by institutional investors.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.